Tuberculin skin tests following Bacille Calmette Guerin vaccination in Africa: a protocol for systematic review and meta-analysis

Chinonyelum Thecla Ezeonu, Richard Chinaza Ikeagwulonu, Uzoma Vivian Asiegbu, Dorathy Chinwe Obu, Datonye Christopher Briggs

Corresponding author: Datonye Christopher Briggs, Department of Pediatrics, Rivers State University Teaching Hospital, Port Harcourt, Rivers State, Nigeria. datonyebriggs2007@gmail.com

Received: 26 Jun 2021 - Accepted: 17 Dec 2021 - Published: 05 Jan 2022

Keywords: Tuberculosis, Mycobacterium tuberculosis, Bacille Calmette Guerin, tuberculin skin test, tuberculin unit, purified protein derivatives

Copyright: Chinonyelum Thecla Ezeonu et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Chinonyelum Thecla Ezeonu et al. Tuberculin skin tests following Bacille Calmette Guerin vaccination in Africa: a protocol for systematic review and meta-analysis. Pan African Medical Journal. 2022;41(12). 10.11604/pamj.2022.41.12.30535

Available online at: https://www.panafrican-med-journal.com/content/article/41/12/full

Tuberculin skin tests following Bacille Calmette Guerin vaccination in Africa: a protocol for systematic review and meta-analysis

Chinonyelum Thecla Ezeonu¹, Richard Chinaza Ikeagwulonu², Uzoma Vivian Asiegbu¹, Dorathy Chinwe Obu¹, Datonye Christopher Briggs³&

¹Department of Pediatrics, Alex Ekwueme Federal University Teaching Hospital Abakaliki, Ebonyi State, Nigeria, ²Department of Medical Laboratory Science, Alex Ekwueme Federal University Teaching Hospital Abakaliki, Ebonyi State, Nigeria, ³Department of Pediatrics, Rivers State University Teaching Hospital, Port Harcourt, Rivers State, Nigeria

*Corresponding author
Datonye Christopher Briggs, Department of Pediatrics, Rivers State University Teaching Hospital, Port Harcourt, Rivers State, Nigeria
Abstract

Tuberculin reactivity following tuberculin skin test which is the most common measure of the effect of the Bacille Calmette Guerin (BCG) vaccination has remained complex. This protocol is aimed to assess the effect of BCG vaccine on tuberculin skin test in Africa as a guide to better understanding or resolving this complexity. A search strategy is developed using MeSH, key words, text words, and entry terms. Five databases will be searched, including PubMed, African Journals Online (AJOL), Google Scholar, Research Gate, and Cochrane Library. Only observational studies conducted in Sub-Saharan Africa and retrievable in English language will be included. The primary measurable outcome of this study is pooled prevalence of positive tuberculin skin tests. Secondary outcomes are factors that influence Tuberculin Skin Test (TST) positivity such as BCG type, the dose of BCG, age at BCG vaccinates, time/interval between BCG vaccination and TST, and type of tuberculin unit used for TST. Identified studies will be screened and selected based on inclusion criteria. Data will be extracted into Zotero, Microsoft Excel and CMA software. Both quality scores and the risk of bias for individual studies will be reported. Studies will be assessed for methodological, clinical, and statistical heterogeneity. Funnel Plots will be used for assessing publication bias. The results will be presented in tabular format in addition to a narrative synthesis. The pooled prevalence of effect of BCG vaccine on TST in Africa will be examined in relation to factors that influence TST positivity.

Introduction

Tuberculosis is a chronic disease posing a public health challenge particularly in resource poor countries [1]. In 2017, about 10 million new cases of TB with 1.6 million deaths were reported globally [2]. However, one surest way of preventing TB globally had been through vaccination and Bacille Calmette Guerin (BCG) vaccine has been widely used across continents. The BCG vaccine is routinely given to protect individuals, especially children, from serious forms of tuberculosis disease [3]. In Africa and in most TB endemic countries, the vaccine is usually administered around birth to prevent severe TB in infants. Importantly, asymptomatic latent tuberculosis infection can be detected through performance of tuberculin skin test (TST), a procedure which utilizes a purified protein derivative (PPD) of heat killed live cultures of mycobacteria injected intra-dermally into the forearm to demonstrate delayed hypersensitivity response to the PPD, which fully occurs within 48-72 hours [4].

Tuberculin reactivity which can either be positive or negative following tuberculin skin test has been the most common measure of the effect of the BCG vaccination. Positive tuberculin skin test has been reported in previously BCG vaccinated individuals and in circumstances such as recent contact with another person with infectious TB or continual exposure to populations with a high prevalence of TB [5,6]. Conditions such as cross reactivity of the PPD with other non-tuberculous mycobacterial organisms, presence of morbidities such as HIV co-infection, and the immune status of the individuals have been reported to affect TST results [4,7,8]. Vaccination with live viruses such as live-measles, may cause false-negative tuberculin reactions [9] while anergy can occur in individuals with impaired cellular immune function such as those with severe malnutrition or immune-deficiency diseases. Also, the technique of BCG administration, dose, the age at which vaccine was administered, gender, socioeconomic status, degree of TB burden in the community, the people’s genetic background, ethnicity, the manufacturer of the vaccine, the interval between vaccination and testing, have been reported to affect the risk and degree of a reactive PPD tuberculin skin test following BCG vaccination [10-16]. Notwithstanding these confounding effects of BCG on PPD tuberculin test readings, exposure to TB through contacts is more likely to increase positive PPD [17,18], hence, individuals from countries with a high or moderate incidence of TB are more likely to have reactive PPDs than those from countries of low incidence. Nonetheless, reports from various studies have
shown conflicting evidence in interpreting a true-positive Tuberculin Skin Test (TST) secondary to an infection and a false-positive test due to a previous vaccination [19,20]. Tuberculin test reading of 10mm or more in the absence of high risk of tuberculosis, has been generally accepted as positive result, in most studies [21,22]. The US Preventive Services Task Force (USPSTF) without any specific recommendation regarding BCG effects on PPD readings, generally states that reactions >10 mm should not be attributed to prior BCG vaccine [23]. Tuberculin skin test measurement of 5mm had been reported among the immune-compromised individuals [4].

In some studies, increased tuberculin reactivity was seen in individuals that received high-dose of the vaccine [24], those whose vaccination or revaccination were given later in life [25-27], and in cases of booster phenomenon [28]. The multipuncture technique has been reported to have significantly resulted in fewer conversions to positive tuberculin skin tests than the intradermal method [29]. In all, the effect of BCG vaccine on tuberculin test reactivity is quite complex making the use of this test to diagnose latent tuberculosis difficult. The uncertainty of the effect of BCG vaccination on TST results and interpretation may affect TB control and treatment. Due to the public health concern of Tuberculosis, it has thus become necessary to conduct a meta-analysis of studies that reported the relationship between TST reactivity in BCG vaccinated and non-vaccinated individuals for better understanding and guide.

Aim: the main objective of this review is to assess the effect of Bacille Calmette Guerin vaccine on tuberculin skin test in Africa.

Study objectives: 1) to determine the pooled prevalence of positive tuberculin skin tests in Africa. 2) To determine the prevalence of positive tuberculin skin tests in subgroups such as children, adults, previously BCG vaccinated, and non-vaccinated individuals in Africa. 3) To determine the factors that influence TST positivity such as BCG type, the dose of BCG, age at BCG vaccination, time/interval between BCG vaccination and TST, type of tuberculin unit used for TST, the strength of tuberculin unit used for TST, presence, and absence of BCG scar.

Review questions: 1) what is the pooled prevalence of positive tuberculin skin tests in Africa? 2) What is the prevalence of positive tuberculin skin tests in subgroups such as children, adults, previously BCG vaccinated, and non-vaccinated individuals? 3) What are the factors that influence TST positivity?

Methods

Study design: this is a protocol for systematic review and meta-analysis of observational studies that reported on the effect of Bacille Calmette Guerin vaccine on tuberculin skin test in Africa. Other types of study designs are excluded including interventional studies, comments, and editorials. There is no time restriction on eligible primary studies.

Inclusion criteria: a) observational studies (cohort, cross-sectional, case-control, historical cohort). b) Studies of all years that are published or retrievable in the English language. c) Studies that are available in electronic databases. d) Studies that report the proportion of positive Tuberculin skin test cases (this is the primary outcome measure) and/ or secondary outcome which are factors that influence TST positivity.

Exclusion criteria: a) studies without proportion of positive Tuberculin skin test cases. b) Studies that included known contacts of active TB cases. c) Studies that included people with TB infection or disease. d) Narrative reviews, interventional and experimental studies, and letters to the editor e) Studies that are not reported or retrievable in the English language.

Study characteristics: the PICOS is as follows: participants are individuals who received tuberculin skin test with or without BCG vaccination in Africa. Intervention: there is no intervention. Comparator: there is no comparator. Outcome: the
primary outcome is the proportion of positive tuberculin skin tests. The measurable secondary outcomes are factors that influence TST positivity. Filters used for subgroups are children, adults, and previously BCG vaccinated individuals.

**Information sources:** the search will employ sensitive topic-based strategies designed for each database. The five databases to be searched are PubMed, African Journal Online (AJOL), Google Scholar, Research Gate, and Cochrane Library. The study will retrieve only observational studies written in the English language. There is no time frame or restriction in the inclusion of publications.

**Search strategy:** the search strategy will include MeSH terms, text words, entry words, and keywords. The search strategies that will be used are shown in Table 1.

**Data extraction:** the data will be extracted and managed using the following tools: i). Zotero software, ii) Microsoft Excel, and iii) Comprehensive Meta-analysis software (CMA) version 3.

**Screening:** studies will be searched using the search strategy. Six levels of data screening will be involved. Level 1: screening to select only observational studies while other study designs are excluded. Level 2: screening of all selected observational studies by their titles and abstracts using MeSH terms, keywords, and entry terms. Level 3: screening of the selected studies by full-text reading, using the same strategy. Level 4: snowballing of the literature using included studies. Level 5: screening for primary and secondary outcomes. Level 6: screening for risk of bias using NIH quality assessment for observational studies and Cochrane risk of bias to strengthen the evidence.

**Selection process and review:** five reviewers are involved in this study. A pair of reviewers will independently screen studies from each database, assessing the studies for inclusion and or exclusion. Conflicts will be resolved by a third independent reviewer. All reviews are blinded. The screening and deduplication will be done in Zotero software. Screened studies will be exported into Microsoft Excel, to be arranged for data analysis. Studies will be selected based on eligibility criteria and primary measurable outcome. Authors of studies with missing data will be contacted via email and telephone.

**Data collection:** the following data items will be extracted from each eligible study into Microsoft Excel: i) First author’s surname, year of publication of the study, year of study, country of study, study design ii) Sample size iii) Type and dose of BCG, age at BCG vaccination, the interval between BCG vaccination and tuberculin skin testing, number of subjects that received BCG vaccine, presence or absence of BCG scar, number of positive or negative TST results, type and strength of tuberculin test/antigen used, response rate/wheal size to tuberculin test at specific diameters, and indication for TST. Others are age group studied, age when TST was given, age when BCG was given, gender, socioeconomic status, means of determining BCG vaccination, the technique for applying and reading the test, the immunological status of the subjects, presence of medical conditions in the studied population such as cancer, Diabetes Mellitus, AIDS Nutritional status and BCG coverage rate. Data from Microsoft Excel will be exported to CMA software for meta-analysis.

**Risk of bias:** the risk of bias in included studies will be assessed for the individual studies using the National Institute of Health (NIH) Quality assessment tool for observational cohort and cross-sectional studies. This will be cross-checked with the Cochrane tool of risk of bias assessment for the strength of the body of evidence. Studies with extreme bias will be excluded after assessment in the following areas: 1. Method of testing and reporting at the outcome level. 2. Reporting of study; prevalence with confidence interval or number of positive cases/sample size, as reported at the outcome level. 3. Heterogeneity will be assessed at the study level. 4. Publication bias will be assessed at the study level.
**Assessment of meta-bias:** to test for heterogeneity Cochrane’s Q value, $I^2$, $T^2$ will be used. $I^2$ values of less than 40% will be considered low heterogeneity, values > 40 to ≤75 % moderate while values > 75% are high. The effect sizes to be used are prevalence with a confidence interval (CI, 95%).

**Data synthesis:** both narrative and quantitative analysis will be performed. All studies that report the primary outcome with or without secondary outcomes will be included for systematic review, with all measurable outcomes and sample size reported in a tabular format. Studies with primary indices that can be converted to prevalence will be converted in the CMA software version 3. Quantitative data will include pooled prevalence, standard error and 95% CI. Both random and fixed effect models will be assessed, and the appropriate model will be taken based on the forest plots. Subgroup analysis will be done using categorical factors such as age and BCG vaccination status. Meta-regression will be performed to check for the trend in the prevalence of positive tuberculin skin tests over the years.

**Results**

The study selection process will be summarized in a flow diagram according to the PRISMA 2015 Statement and PRISMA-P Checklist. A table of the search strategy in various databases showing text words, MeSH, and entry terms will be included. A list of included studies will be summarized in a table. Quantitative data such as effect size (prevalence), 95% CI, P values, and relative weights assigned to studies and heterogeneity tests will be included in the forest plots. A table of quality scores and risk of bias of each eligible study will be included. Forest plots to show sub-group analysis will be included. A cumulative meta-analysis to check for trends will also be included.

**Discussion**

This meta-analysis will address important clinical and epidemiological questions about interpreting the TST in patients with previous BCG vaccination which will help health workers to educate patients when offering treatment for latent tuberculosis infection in a setting of previous BCG vaccination, a positive skin test, and no known TB contact. Large or strongly positive skin tests are most probably due to tuberculosis infection rather than BCG.

**Ethics and dissemination:** ethical approval will not be required since this study will be based on published data. The final report of this study will be published in a peer- reviewed scientific journal.

**Competing interests**

The authors declare no competing interests.

**Authors' contributions**

CT conceived the project, CT, RC, UV, DC, and DB designed the study, RC and UV did PubMed searches, screening and review; UV and DC did AJOL searches, screening and review; CT and DC did Google scholar searches, screening and review; while as Cochrane Database and Research gate searches, screening and review was done by CT, RC, DC, and DB respectively. All authors read and approved the manuscript for publication.

**Table**

**Table 1:** search strategy

**References**

1. Adebisi YA, Agumage I, Sylvanus TD, Nawaila IJ, Ekwere WA, Nasiru M et al. Burden of tuberculosis and challenges facing its eradication in West Africa. Int J Infect. 2019;6(3). [Google Scholar]
2. World Health Organization. Global tuberculosis report 2018. ReliefWeb. Accessed June 26, 2021.
3. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3(8): 656-662. PubMed | Google Scholar
4. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis. 1993;17(6): 968-975. PubMed | Google Scholar
5. Centers for Disease Control and Prevention. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the advisory council for the elimination of tuberculosis and the advisory committee on immunization practices. Atlanta, GA. 1996.
6. Bugiani M, Borraccino A, Migliore E, Carosso A, Piccioni P, Cavallero M et al. Tuberculin reactivity in adult BCG-vaccinated subjects: a cross-sectional study. Int J Tuberc Lung Dis. 2003;7(4): 320-326. PubMed | Google Scholar
7. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20): 2060-2067. PubMed | Google Scholar
8. Miret-Cuadras P, Pina-Gutierrez JM, Juncosa S. Tuberculin reactivity in Bacillus Calmette-Guérin vaccinated subjects. Tubercle and Lung Disease. 1996;77(1): 52-58. PubMed | Google Scholar
9. Kupers TA, Petrich JM, Holloway AW, Gme JWS. Depression of tuberculin delayed hypersensitivity by live attenuated mumps virus. The Journal of Pediatrics. 1970;76(5): 716-721. PubMed | Google Scholar
10. Maes M, Verhagen LM, Ortega D, Sánchez GL, Segovia Y, Del Nagol B et al. Influence of Bacille Calmette-Guérin on tuberculin skin testing in Venezuelan Amerindians in high tuberculosis burden areas. J Infect Dev Ctries. 2014;8(2): 176-183. PubMed | Google Scholar
11. Verhagen LM, Hermans PWM, Warris A, de Groot R, Maes M, Villalba JA et al. Helminths and skewed cytokine profiles increase tuberculin skin test positivity in Warao Amerindians. Tuberculosis. 2012;92(6): 505-512. PubMed | Google Scholar
12. Mahomed H, Hawkridge T, Verver S, Geiter L, Hatherill M, Abrahams DA et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis. 2011;15(3): 331-336. PubMed | Google Scholar
13. Lienhardt C, Fielding K, Sillah J, Tunkara A, Donkor S, Manneh K et al. Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med. 2003;168(4): 448-455. PubMed | Google Scholar
14. Dhanawade S, Kumbhar S, Gore A, Patil V. Scar formation and tuberculin conversion following BCG vaccination in infants: a prospective cohort study. J Family Med Prim Care. Jul-Sep 2015;4(3): 384-7. PubMed | Google Scholar
15. World Health Organization. The immunological basis for immunization series: module 5: tuberculosis, update 2011. Accessed June 26, 2021.
16. Rezai MS, Abedi S, Afshari M, Moosazadeh M. Estimating tuberculin skin test reactions among children and teenagers who received the Bacillus Calmette-Guerin vaccination at birth: a meta-analysis. Osong Public Health Res Perspect. 2017;8(1): 3-10. PubMed | Google Scholar
17. Almeida LMD, Barbieri MA, Da Paixão AC, Cuevas LE. Use of purified protein derivative to assess the risk of infection in children in close contact with adults with tuberculosis in a population with high Calmette-Guérin bacillus coverage. Pediatr Infect Dis J. 2001;20(11): 1061-1065. PubMed | Google Scholar
18. Menzies R, Vissandjee B, Amyot D. Factors associated with tuberculin reactivity among the foreign-born in Montreal. Am Rev Respir Dis. 1992;146(3): 752-756. PubMed | Google Scholar
19. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11): 1192-1204. PubMed | Google Scholar
20. Wang L. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax. 2002;57(9): 804-809. PubMed | Google Scholar
21. Gustafson P, Lisse I, Gomes V, Vieira CS, Lienhardt C, Naucler A et al. Risk factors for positive tuberculin skin test in Guinea-Bissau. Epidemiology. 2007;18(3): 340-347. PubMed | Google Scholar
22. Turnbull L, Bell C, Child F. Tuberculosis (NICE clinical guideline 33). Arch Dis Child Educ Pract Ed. 2017;102(3): 136-142. PubMed | Google Scholar
23. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW et al. Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement. JAMA. 2016;316(9): 962-9. PubMed | Google Scholar
24. Ashley MJ, Siebenmann CO. Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts. Can Med Assoc J. 1967;97(22): 1335-1339. PubMed | Google Scholar
25. Menzies R. Tuberculin skin testing. in: Reichman Lb, Hershfield Es, Editors. Tuberculosis: a comprehensive international approach. 2nd Ed. New York. marcel Dekker. 2000.
26. Karalliedde S, Katugaha LP, Uragoda CG. Tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle. 1987;68(1): 33-38. PubMed | Google Scholar
27. Sepulveda RL, Burr C, Ferrer X, Sorensen RU. Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with Bacillus Calmette-Guérin at birth in Santiago, Chile. Pediatr Infect Dis J. 1988;7(8): 578-581. PubMed | Google Scholar
28. Sepulveda RL, Ferrer X, Latrach C, Sorensen RU. The influence of Calmette-Guérin Bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis. 1990;142(1): 24-28. PubMed | Google Scholar
29. Landi S, Ashley MJ, Grzybowski S. Tuberculin sensitivity following the intradermal and multiple puncture methods of BCG vaccination. Can Med Assoc J. 1967;97(5): 222-225. PubMed | Google Scholar

**Table 1: search strategy**

| Database       | Search strategy                                                                 |
|----------------|---------------------------------------------------------------------------------|
| Pubmed         | (((Tuberculin Tests) OR "Tuberculin Test"[Mesh] OR Purified Protein Derivative of Tuberculin) OR "Tuberculin"[Mesh]) AND "BCG Vaccine"[Mesh] OR Calmette Guerin Bacillus Vaccine) AND "Africa"[Mesh] |
| AJOL           | (Tuberculin Tests) OR "Tuberculin Test" OR Purified Protein Derivative of Tuberculin) OR "Tuberculin" AND "BCG Vaccine" OR Calmette Guerin Bacillus Vaccine) AND "Africa" |
| Google scholar | (((Tuberculin Tests) OR "Tuberculin Test"[Mesh] OR Purified Protein Derivative of Tuberculin) OR "Tuberculin"[Mesh]) AND "BCG Vaccine"[Mesh] OR Calmette Guerin Bacillus Vaccine) AND "Africa"[Mesh] |
| Research gate  | Tuberculin Tests OR "Tuberculin Test" OR Purified Protein Derivative of Tuberculin OR "Tuberculin" AND "BCG Vaccine" OR Calmette Guerin Bacillus Vaccine AND "Africa" |
| Cochrane Library | Tuberculin Tests OR "Tuberculin Test" OR Purified Protein Derivative of Tuberculin OR "Tuberculin" AND "BCG Vaccine" OR Calmette Guerin Bacillus Vaccine AND "Africa" |